ALLIANCE-TO-END-PLASTIC
7.5.2020 13:02:08 CEST | Business Wire | Press release
The Alliance to End Plastic Waste (the Alliance) today announced a partnership with the ASASE Foundation to support women entrepreneurs working to reduce plastic litter in the community. The initiative called Closing the Loop uses a circular economy model to enable local communities to benefit from discarded plastic waste by collecting, reprocessing and reselling it.
Closing the Loop kicks off the Alliance’s support for projects based in Africa. It was first launched by ASASE in 2018 to provide seed money to equip a plastic waste reprocessing plant and offer technical and business management training to women entrepreneurs to run the recycling plant for profit. In the first twelve months, the project created eight jobs within the community and diverted 35 (metric) tons of plastic from waste. By partnering with the Alliance, the capacity of the reprocessing plant will increase to divert 2,000 (metric) tons of plastic waste per year and create even more jobs.
“A key pillar of ending plastic waste in the environment is the sustainable impact it will bring to the well-being of local communities. Our partnership with ASASE is especially meaningful because Closing the Loop is the right step towards a circular economy model. It directly benefits those living in areas which don’t have access to plastic waste collection and sorting systems. This initiative is a simple but scalable action, supporting the inspiring women of Ghana who are building communities towards a path to end plastic waste in the environment,” said Jacob Duer, President and CEO, Alliance to End Plastic Waste.
“What we value most in our partnership with the Alliance to End Plastic Waste is the access to the expertise in waste management, which we can leverage now in our project, effectively multiplying the impact of the funding provided by the Alliance to our project,” comments Dana Mosora, ASASE Foundation Founder and Managing Director.
The partnership has also opened the possibility to bring in expertise from academic partner, the Swiss Federal Institute of Technology, in areas of developing new end market applications and concepting a new financing system for the management of plastic waste in Ghana.
The recycling plant processes a range of plastic waste from water sachets (LDPE) to shampoo and detergent bottles (HDPE) and large cooking oil containers (HDPE), converting it into regrinds. The regrinds are then sold to recyclers to make items such as pavement blocks, sheets for construction and basins and liners, most of which goes back into the community.
About:
The Alliance to End Plastic Waste is a not-for-profit organization bringing together industry, government, communities, and civil society in the fight to end plastic waste.
ASASE Foundation enables Ghanaian women entrepreneurs to play a key role in cashing-in on the plastic waste trash of Accra for the benefit of their own communities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200507005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom